Northwestern University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Northwestern University sits in the top decile of US sponsors by registered trial count (#23 of 15,742 sponsors by registered trial count).

1,209 total trials 187 currently recruiting 767 completed early-phase tilt top decile by trial count

Northwestern University: 1,209 sponsored US clinical trials, 187 recruiting.

Northwestern University sponsors 1,209 registered US clinical trials on ClinicalTrials.gov, 187 of them currently recruiting, and 767 completed. 114 of these trials are in Phase 3-4 (later-stage) and 295 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 11 trials.

Top-decile sponsor footprint

Northwestern University ranks in the top decile of sponsors by registered trial count (#23 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 50/100

767 of 912 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,209 total, page 23 of 25

COMPLETED NA

Improving Motivation for Physical Activity in Arthritis Clinical Trial

NCT00248105

COMPLETED

Incidence of Obstructive Sleep Apnea in Pregnancy

NCT00462306

COMPLETED Phase 4

The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis

NCT00179959

TERMINATED Phase 1

Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases

NCT00278564

COMPLETED Phase 2

Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00234052

COMPLETED Phase 3

Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study

NCT00225017

COMPLETED Phase 2

Stress Management for Patients With Multiple Sclerosis

NCT00147446

COMPLETED NA

Translating the DPP Into the Community

NCT00302042

COMPLETED Phase 1

Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor

NCT00711243

COMPLETED Phase 2

Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome

NCT00466921

COMPLETED NA

Problem-solving: A Stroke Caregiver Early Intervention

NCT01141738

COMPLETED Early Phase 1

Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer

NCT00278369

TERMINATED Phase 4

A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression

NCT00166712

TERMINATED Phase 2

Crohn's Disease Stem Cell Transplantation

NCT00271947

COMPLETED Phase 2

Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH

NCT00267670

TERMINATED Phase 1

Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer

NCT00281996

COMPLETED Phase 2

Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy

NCT00278629

COMPLETED Phase 1

Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma

NCT00301067

COMPLETED

Traumatic Ulnar Translocation of the Carpus

NCT01258166

COMPLETED

Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

NCT00530010

COMPLETED

Radiolabeled Glass Beads in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery

NCT00532740

COMPLETED

SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function

NCT00225082

COMPLETED Phase 1

Stem Cell Injection for Peripheral Vascular Disease

NCT00278603

COMPLETED NA

Improving Aspirin Use in Diabetes: A Cluster Randomized Trial

NCT00262977

COMPLETED NA

Effect of Timing on Efficacy of Morphine Analgesia After 2-chloroprocaine Anesthesia

NCT00487084

COMPLETED NA

Make Better Choices Study

NCT00113672

COMPLETED Phase 4

Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin

NCT00338104

TERMINATED Phase 2

High-Dose Esterified Estrogens in Treating Postmenopausal Women With Metastatic Breast Cancer That Has Failed Previous Hormone Therapy

NCT00131924

COMPLETED Phase 4

Brain Imaging of Lidoderm for Chronic Back Pain

NCT01515540

COMPLETED

Coagulation Factor Changes Associated With Postpartum Hysterectomies

NCT00456547

COMPLETED NA

Partner Assistance in Learning and Performing Skin Self-Examination

NCT01013844

TERMINATED Phase 1

Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis

NCT00282438

TERMINATED Phase 1

Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL

NCT00089284

COMPLETED Phase 3

Prevention of Weight Gain in Adult Patients With Type 2 Diabetes Treated With Pioglitazone

NCT00737347

COMPLETED

Circadian Rhythms and Sleep in Familial DSPS and ASPS

NCT00246454

COMPLETED NA

Improving Functioning in Peripheral Arterial Disease

NCT00106327

TERMINATED Phase 1

Hematopoietic Stem Cell Support in Vasculitis

NCT00278512

COMPLETED Phase 1

In Vivo Angiostatin Generation Using Tissue Plasminogen Activator and Captopril in Treating Patients With Progressive Metastatic Cancer

NCT00086723

COMPLETED Phase 1

Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00073866

COMPLETED NA

Effect of 4-Hydroxytamoxifen Gel on Breast Density, Salivary Sex Steroids, and Quality of Life in Premenopausal Women

NCT00084344

TERMINATED Phase 3

Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation

NCT00058188

COMPLETED

Effect of Tamoxifen on Breast Density in Premenopausal Women With Breast Cancer or High Risk for Breast Cancer

NCT00086749

COMPLETED Phase 3

Serotonin 1A Agonists and Cognition in Schizophrenia

NCT00178971

TERMINATED Phase 2

Genistein in Treating Patients With Localized Prostate Cancer Who Are Planning to Undergo Radical Prostatectomy

NCT00058266

COMPLETED Phase 1

Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma

NCT00057980

COMPLETED

Platelet Count Trends in Pre-eclamptic Parturients

NCT00787241

COMPLETED Phase 2

Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer

NCT00058006

COMPLETED Phase 2

Immune Ablation and Hematopoietic Stem Cell Support in Patients With Systemic Lupus Erythematosus: A Phase II Study

NCT00271934

TERMINATED Phase 1

Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism

NCT00282412

COMPLETED NA

The Effect of Combined Spinal-Epidural Analgesia on the Success of External Cephalic Version (ECV) for Breech Position

NCT00565383

← Previous Page 23 of 25 Next →

Phase Distribution

PhaseTrial count
Phase 1 132
Phase 2 163
Phase 3 36
Phase 4 78

What is open in the Northwestern University pipeline

187 recruiting of 1,209 indexed (15% open); 767 completed (63%).

Phase mix: 114 late (III/IV) vs 295 early (I/II) (early-phase heavy).

Top condition: Depression (11 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Northwestern University: open-pipeline peers nationwide

Peers matched on 1,209 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

Northwestern University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 12%14%16%18%20% Total trials Recruiting share Northwestern UniversityEmory UniversityUniversity of PittsburghNYU Langone HealthUniversity of Alabama at BirminghamBrigham and Women's HospitalIncyte CorporationNationwide Children's HospitalUniversity of Michigan Rogel Cancer Center
Northwestern University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Northwestern University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,209 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

What to do with this Northwestern University page

1,209 registered trials is a research-attention snapshot, not an endorsement of Northwestern University or any single study.

  • 187 of Northwestern University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Depression is the condition Northwestern University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Northwestern University pipeline card: 1,209 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.